...to stop influx of neutrophils and reduce lung injury in a rat model of ARDS. NeXstar Pharmaceuticals Inc....

...more effective than amphotericin B or The Liposome Co Inc.'s Abelcet , and equivalent to NeXstar Pharmaceuticals Inc....

...NXTR originally filed the suit in May 1993. The Liposome Co. Inc. (LIPO), Princeton, N.J. NeXstar Pharmaceuticals Inc....

...in 1991 to commercialize the procedure. In 1995, NeXagen and Vestar Inc. merged to become NeXstar...

...Inc. last June. Gilead's first foray into cancer drug development was its 1999 acquisition of NeXstar Pharmaceuticals Inc....

...Inc. in 1991 to commercialize SELEX. In 1995 NeXagen and Vestar Inc. merged to become NeXstar...

...it needs to expand into new therapeutic areas since 1999. At that time, it bought NexStar Pharmaceuticals Inc....

...in 1991 to commercialize the technology. In 1995 NeXagen and Vestar Inc. merged to become NeXstar...

...the regulatory strategy and building a commercial infrastructure. The CEO, Pat Mahaffy, had been at NeXstar...
...building a commercial team," said Pollard-Knight. "We saw it as a very late-stage product play." NexStar Pharmaceuticals Inc....

...the 1990s, Gold founded NeXagen, which became NeXstar following a merger with Vestar. In 1999, NeXstar...